

INDEX

Chronic Obstructive Lung Disease is abbreviated as COLD throughout this index.

ACROLEIN

- alpha₁-antitrypsin effect, 436
- alveolar macrophage effects, 432
- cilioinhibitory effect, 295
- gas phase component, 294, 417

ADDICTION

- cessation of smoking, relationship, 468, 481, 485

ADDITIVES

- (See also **MENTHOL; PHENOL**)
- low yield cigarettes, increasing use, 13, 352, 354

ADOLESCENTS

- (See also **CHILDREN**)
- increased cough in smokers, 6
- prevalence of cough and amount smoked, 64
- sex differences in prevalence of respiratory symptoms, 66
- small airways dysfunction in smokers, 37, 427
- smoking rates with smoking and nonsmoking parents, 506

ADVERTISING

- (See also **MASS MEDIA**)
- government regulation of tobacco advertising, 506-507, 514, 520, 527
- promotion of cardiovascular risk reduction, 508
- smoking cessation or reduction effects, 457

AGE DIFFERENCES

- airflow obstruction incidence, 103
- cessation rates in post-MI patients, 475
- cessation success, 468
- chronic airflow obstruction, prevalence, 78
- chronic bronchitis, prevalence, 46-47
- COLD mortality, 191-192, 197, 203-205

AGE DIFFERENCES—Contd.

- cough and phlegm, prevalence, 48, 65-68
- emphysema, severity in smokers and nonsmokers, 126, 241-242
- initiation of smoking and COLD mortality, 209
- lung pathology in smokers, 124-125, 231
- mucociliary transport, 283
- pulmonary function, 6
- pulmonary function in children of smoking parents, 398
- pulmonary function, rate of decline, 9, 137
- reductions in smoking with community intervention studies, 511-512
- small airways dysfunction, 9, 29-30, 32-35, 37-39, 136-137

AIR POLLUTION

- (See also **PASSIVE SMOKING**)
- airflow obstruction relationship, 105
- bronchitis morbidity factor, 212
- COLD mortality factor, 192
- lung clearance effect, 424
- particulates exposure compared with smoking, 417
- workplace levels and pulmonary function, 31

ALCOHOL CONSUMPTION

- abstinence in pregnancy, 462
- airflow obstruction relationship, 105-106

ALLERGY

- atopy and pulmonary function, 106
- lung hypersensitivity and airflow obstruction, 104-105, 118
- skin test reactivity and incidence of airflow obstruction, 103

INDEX

Alpha₁-antiprotease *See* **ALPHA₁-ANTITRYPSIN**

ALPHA₁-ANTITRYPSIN

- antiprotease activity, 262-264
- deficiency in panacinar emphysema, 234-235
- elastase inhibition, 8, 11, 301
- genetic deficiency, 9-10, 83, 104, 118, 129-137, 261-262, 275
- oxidants and decreased inhibitory capacity, 273-274, 435
- papain elastolysis, inhibitor, 265
- tar and nicotine content effect on elastase inhibition, 340
- tobacco smoke effects, 434-437

Alpha₁-proteinase inhibitor

See **ALPHA₁-ANTITRYPSIN**

ALVEOLAR MACROPHAGES

- changes in smokers, 255-257, 259, 261, 278-279
- changes induced by tobacco smoke, 431-434
- emphysema pathogenesis, role, 268-270
- increased numbers in smokers, 11, 270-271, 301
- increased numbers with nitrogen dioxide, 276
- lung clearance mechanisms, role, 423-424
- neutrophil chemotaxis, role, 258
- toxicity of cigarette smoke, 279-280

ALVEOLITIS

- smoking relationship, 255

AMISH

- COLD mortality, 213

AMMONIA

- gas phase component, 294, 417

ANGINA

- contraindication for nicotine chewing gum, 477

Antibodies *See* **IMMUNE SYSTEM**

ANTISMOKING CAMPAIGNS

(*See also* **SMOKING INTERVENTION STUDIES**)

- smoking behavior, effect, 457
- smoking cessation at prenatal clinics, effect, 462-463

ASBESTOS

- cessation success in exposed shipyard workers, 482-483

ASTHMA

- bronchoconstrictive effect of smoke inhalation in asthmatics, 428-429
- children of smoking parents, 389, 392-393, 403
- mortality in California physicians, 211
- nonsmokers exposed to tobacco smoke, 403, 405-406
- reversibility of airflow obstruction, 75

ATROPINE

- cilioinhibitory effect, 295

AVERSIVE SMOKING

- cessation effectiveness, 469

BACTERIA

- clearance from respiratory tract, 281
- macrophage bactericidal capacity in smokers and nonsmokers, 278-279
- reduced resistance to infection in smoke-exposed animals, 280

BEHAVIOR MODIFICATION

- physicians' efforts to get patients to quit, 455
- social reinforcement in community intervention trials, 506

BIRTHWEIGHT

- maternal smoking relationship, 461, 464-465

BRONCHIOLITIS

- childhood, association with subsequent panacinar emphysema, 236

- COLD, role in pathogenesis, 11
- pathology, 223, 230-231

- smoking relationship, 242, 255-256

BRONCHITIS

(*See also* **MUCUS HYPERSECRETION**)

- abnormalities in regional gas exchange, 22
- aerosol clearance effects, 292-293
- childhood, association with panacinar emphysema, 236
- children of smoking parents, 13, 393, 405
- definition, 45-46, 224
- excessive morbidity in Britain, 212
- mortality and age of smoking initiation, 209-210

INDEX

BRONCHITIS—Contd.

- mortality and depth of inhalation, 208
- mortality and smoking habit, 201
- mortality in physicians, 211
- mucociliary dysfunction, 12, 283, 297-302
- natural history, 115
- particulate phase components, role, 426
- pathology, 227, 229
- prevalence, 46
- smoking relationship, 48, 255

BRONCHOCONSTRICTION

- dogs exposed to cigarette smoke, 429
- induction by cigarette smoke, 428, 430
- inhalation pattern relationship, 349-350
- low yield cigarettes effect, 341

CADMIUM

- induction of emphysematous lesions in animals, 276
- tobacco smoke component, 426

CARBON DIOXIDE

- gas phase component, 417

CARBON MONOXIDE

- breath test to demonstrate smoking effects in pregnant women, 464
- breath test to validate self-reported cessation, 460, 463
- gas phase component, 417
- increased alveolar epithelial permeability, role, 430
- indoor air pollutant, 366, 383
- low-tar and low-nicotine cigarettes, yields, 345-346

CARBOXYHEMOGLOBIN

- asthmatics exposed to tobacco smoke, levels, 403
- inhalation pattern relationship, 345, 349
- measure of carbon monoxide absorption, 366, 383
- nonsmokers exposed to tobacco smoke, levels, 384

CARCINOGENESIS

- consequence of mucociliary dysfunction, 301

CASEIN

- chemotaxis of polymorphonuclear leukocytes, effect, 433

CATALASE

- reduction of smoke effects on alpha₁-protease inhibitor, 436

CERULOPLASMIN

- prevention of alpha₁-antitrypsin oxidation, 274

CESSATION OF SMOKING

(See also REDUCTION OF SMOKING)

- cardiopulmonary function improvement, 465
- COLD incidence and progression effects, 7-8
- COLD mortality relationship, 10, 210-211, 214
- community intervention studies, 15, 503-528
- cough and phlegm reduction, 9, 48, 137
- emphysema morbidity and mortality, 126
- emphysema severity in ex-smokers, 241-242
- emphysematous changes, effect, 127-129
- lung clearance effects, 430
- mechanical properties of lungs, effect, 123
- morbidity and mortality reduction, 465
- mucociliary transport effects, 293, 300
- parents, effect on children's asthma, 403
- physicians, 456
- pulmonary function effects, 9, 227, 232, 242
- pulmonary function effects, rate of decline, 9, 116-118, 137
- reasons given by ex-smokers, 457
- respiratory symptoms in ex-smokers, 67
- role of physicians, 14, 455-488
- sex differences in pulmonary function effects, 104
- small airways function effects, 11, 40-42, 44, 137

CHEST INFECTIONS

- airflow obstruction, role in etiology, 83, 107

CHILDREN

(See also ADOLESCENTS)

- influence on parental smoking cessation, 468

INDEX

CHILDREN—Contd.

- pulmonary function effects of smoking, 398
- respiratory illnesses and subsequent airflow obstruction, 104, 106, 118
- respiratory infections and COLD susceptibility, 7
- respiratory symptoms, parental smoking relationship, 13, 388–389, 392–393, 397–398, 402–403, 405
- school-based prevention programs, 519–524

CHLORAMINE-T

- inhibitory capacity of alpha₁-antitrypsin, effect, 273–274, 436

Chronic airflow obstruction See

PULMONARY FUNCTION

CIGAR SMOKERS

- COLD mortality, 10, 211–212, 214
- cough and phlegm prevalence, 48
- emphysema incidence at autopsy, 240

- former cigarette smokers, 460

Cilia See MUCOCILIARY TRANSPORT

CORONARY HEART DISEASE

- contraindication for nicotine chewing gum, 477

COTININE

- nicotine exposure in nonsmokers, measure, 13, 383, 405
- urinary levels in children of smoking mothers, 397

COUGH

(See also MUCUS HYPERSECRETION)

- children of smoking parents, 388
- contribution to pulmonary clearance, 300
- increase in smokers, 6
- low yield cigarettes effect, 336–339, 354
- prevalence in smokers vs. nonsmokers, 9
- tobacco smoke exposure as factor, 386

CREATININE

- urinary levels in children of smoking mothers, 397

CROSS-CULTURAL STUDIES

- COLD mortality, 10–11, 212–214

CYSTIC FIBROSIS

- impairment of mucociliary transport, 283
- submucosal gland enlargement, 225

DIABETES

- contraindication for nicotine chewing gum, 477

EDUCATIONAL ATTAINMENT

- cessation of smoking, relationship, 462, 468

ELASTASE

- experimental induction of emphysema, 8, 122–123, 134, 266–270
- increase in people deficient in alpha₁-antitrypsin, 262
- increased activity in smokers, 271, 301
- inhibition by alpha₁-antitrypsin, 301
- inhibition by protease inhibitors, 434–435, 437
- low yield cigarettes effects, 340
- pathogenesis of COLD, role, 11
- physiochemical conditions that modify kinetics, 272–273
- proximity in elastin degradation, role, 272
- release by macrophages and neutrophils, 257–258, 271–272, 301, 432–434

ELASTIN

- chemoattractant for blood monocytes, 258
- degradation by elastase, 8
- degradation by elastase, role of proximity, 272
- degradation by papain, 265
- synthesis and repair, cigarette smoke effect, 14, 438–439

EMPHYSEMA

- age of smoking initiation and mortality, 209–210
- amount smoked and severity, 11, 137
- animal models, 275–278, 433
- bronchiolitis as precursor, 256
- COLD disease process, 21
- definition and characterization, 119–120
- detection, 120
- gas phase components, role, 426
- irreversibility, 75

INDEX

EMPHYSEMA—Contd.

- lung clearance mechanisms effect, 424
- mechanical properties of lungs in etiology, 122-123
- mortality in physicians, 211
- oxidants in pathogenesis, 426-427
- pathogenic mechanisms, 11-12, 261, 275-301, 431, 435, 437
- pathology, 223, 226, 230-242
- peripheral airway resistance, 22
- protease-antiprotease imbalances in pathogenesis, 11, 262, 270-278, 301, 339-340
- pulmonary function, 26, 121-122
- quantification, 120-121
- smoking relationship, 8, 10, 125-135, 255

ESOPHAGITIS

- contraindication for nicotine chewing gum, 477

EXERCISE

- cessation in post-MI patients, effect, 475
- lung deposition of aerosols, effect, 421
- promotion in community intervention studies, 508

EYES

- irritation following acute exposure to tobacco smoke, 13, 386-387, 405

FAMILY

- influence of support on smoking cessation, 457, 485, 506
- recidivism prevention in post-MI patients, 475

FIBROBLASTS

- membrane damage caused by tobacco smoke, 438

FIBROSIS

- lung clearance mechanisms, effect, 424

FILTER CIGARETTES

(See also **LOW YIELD CIGARETTES**)

- amount smoked and prevalence of mucus hypersecretion, 65
- cilioinhibitory capacity, 287
- filter use and cessation probability, 469
- mucociliary transport effects, 296-297

FILTER CIGARETTES—Contd.

- pulmonary function effects, 116

GENETIC FACTORS

- alpha₁-antitrypsin deficiency, 9-10, 83, 104, 118, 129-137, 261-262, 275
- development of airflow obstruction, 104, 106-107

GROUP COUNSELING

- cessation rates in post-MI patients, effect, 475

HEADACHE

- after acute exposure to tobacco smoke, 386

HEXAMETHONIUM

- cilioinhibitory effect, 295

HISTAMINE

- involvement in bronchoconstrictive response to smoking, 428
- reactivity in smokers and nonsmokers, 430
- release in animals exposed to tobacco smoke, 429

HYDROGEN CYANIDE

- ciliotoxicity, 283, 295

HYDROGEN PEROXIDE

- alpha₁-protease inhibition, effect, 436
- enhanced production in alveolar macrophages in smokers, 432
- inactivation of alpha₁-antitrypsin, 274

HYPERKINESIS

- maternal smoking relationship, 461

HYPERTENSION

- cardiovascular risk reduction program, factor, 515
- contraindication for nicotine chewing gum, 477
- pulmonary artery, association with chronic airflow obstruction, 232

HYPERTHYROIDISM

- contraindication for nicotine chewing gum, 477

IMMUNE SYSTEM

- ABH antigens and airflow obstruction, 105
- COLD susceptibility, factor, 7
- smoking effects, 12, 255, 279-281, 301

INDEX

INFLUENZA

increased susceptibility in smokers,
12, 280, 301

Involuntary smoking *See* PASSIVE SMOKING

ISOPRENE

mucociliary transport effects, 295

ISOPROTERENOL

reversal of airways reactivity, 105

LACTATION

inhibition by maternal smoking,
461

LEAD

particulate phase component, 417

LEGISLATION

restrictions on smoking in public
places, 507, 514, 520, 527

LOBELINE

nicotine substitute, 458

LOW YIELD CIGARETTES

(*See also* FILTER CIGARETTES)

additives, 13, 352-354

cessation success and tar yield, 461

COLD mortality, 198, 201, 203

COLD risk, 12-13, 336-341, 354

lung cancer mortality relationship,
339

mucociliary transport effects, 294

particulate concentrations and size,
418-419

research recommendations, 353

respiratory symptoms, 66

smoking behavior effects, 341-348,
354

tar yield and respiratory symp-
toms, 65

LUNG CANCER

aerosol deposition at bronchogenic
carcinoma sites, 422

low yield cigarettes relationship,
339

mortality in smokers, 336

polonium deposition and site of
bronchogenic carcinoma, 424

smoking behavior relationship, 333

smoking relationship, 255

LUNGS

cigarette-induced disease, pathology,
11

growth in children of smoking
mothers, 398

localization of emphysematous le-
sions, 275

LUNGS—Contd.

pulmonary epithelial permeability
and smoking, 430-431, 439

tissue repair, cigarette smoking ef-
fects, 437

Macrophages *See* ALVEOLAR

MACROPHAGES

MARITAL STATUS

cessation of smoking, relationship,
468-469

MASS MEDIA

(*See also* ADVERTISING)

antismoking educational campaigns,
480

community intervention studies, 15,

505-506, 508-514, 523, 526, 528

televised smoking cessation classes,
519

MATERNAL SMOKING

(*See also* PARENTAL SMOKING;
PREGNANCY)

fetal and childhood effects, 461

prenatal smoking and respiratory
infections in children, 393

METHACHOLINE

responsiveness and airways reactiv-
ity, 105

responsiveness and smoking, 428-
429

METHOL

mucociliary transport effects, 295

Minority groups *See* RACIAL/

ETHNIC DIFFERENCES

MORBIDITY

bronchitis in Britain, 212

chronic airflow obstruction, 68-118

chronic mucus hypersecretion, 45-
73

COLD prevalence and inhalation
practices, 209

emphysema, 119-135

improvement following cessation of
smoking, 465

small airways dysfunction, 22-44

smoking and COLD morbidity, 8-10

MORTALITY

cardiovascular diseases, declines re-
lated to risk factor reduction
program, 515

cessation of smoking relationship,
465

COLD, airflow obstruction relation-
ship, 339

INDEX

MORTALITY—Contd.

- COLD, mucus hypersecretion relationship, 339
- COLD, smoking relationship, 8, 10–11, 189–214, 336
- fetal and neonatal, maternal smoking effect, 461
- myocardial infarction patients who quit smoking, 470
- predictive effectiveness of FEV₁, 72

MUCOCILIARY TRANSPORT

- chronic bronchitis, 297–301
- filters, effect, 296–297
- lung clearance of deposited particulates, 423–424
- normal function, 283–286
- smoke constituents, effect, 293–296, 426
- tobacco smoke, effect, 12, 290–296, 301–302, 418, 431

MUCUS HYPERSECRETION

- cigarette smoke effects, 11, 107, 292, 302
- COLD disease process, 21
- COLD mortality relationship, 339
- cough and phlegm, relationship to airflow obstruction, 68–73
- cough and phlegm, relationship to sex and age, 65–68
- cough and phlegm, relationship to smoking, 47–48, 63–65
- inhalation depth relationship, 349
- low yield cigarettes, effect, 336–339, 354
- measurement of cough and phlegm, 45–46
- phlegm in smokers vs. nonsmokers, 9
- prevalence and amount smoked, 137
- prevalence of cough and phlegm, 46–47

MYELOPEROXIDASE

- inactivation of alpha₁-antitrypsin, 274, 436–437

MYOCARDIAL INFARCTION

- cessation of smoking in post-MI patients, 15, 470, 475–476, 480–481, 487
- contraindication for nicotine chewing gum, 477

N-CHLORSUCCINIMIDE

- reduction of activity of alpha₁-antitrypsin, 436

NEUTROPHILS

- changes induced by tobacco smoke, 255–261, 432–434
- chemotaxis inhibition by cigarette smoke, 269–270
- decrease following elastase instillation, 266
- elastase source, 257–258, 267–268, 271–272
- increased numbers in smokers, 11, 256–257, 270–271, 301
- increased numbers with nitrogen dioxide, 276
- migration in response to macrophage chemotactic factor, 258
- toxicity of cigarette smoke, 279–280

NICOTINE

- alpha₁-protease inhibitor effect, 436
- alveolar epithelial permeability effect, 430
- blood levels with nicotine chewing gum, 476
- bronchial reactivity effect in baboons, 430
- bronchoconstriction effect, 428
- chemokinetic factor for neutrophils, 258, 432–433
- compensatory behavior in smokers of low nicotine cigarettes, 421
- DNA synthesis effect, 280
- indoor air pollutant, 366
- machine-determined yields and actual intake, 335–336, 346–347
- mucociliary transport effects, 295
- nonsmokers exposed to tobacco smoke, levels, 383
- particulate phase component, 417
- reinforcer of smoking behavior, 13
- saliva levels to validate cessation reports, 459

NICOTINE CHEWING GUM

- cessation aid, 14, 460, 476–478, 487

NITRIC OXIDE

- mucociliary transport effects, 295

NITROGEN DIOXIDE

- effect on macrophages, 279
- emphysematous lesions in animals, role in induction, 276
- gas phase component, 294
- mucociliary transport effects, 295

INDEX

NITROGEN OXIDES

- acute bronchospasm effects, 428
- epithelial permeability effects, 430-431
- gas phase component, 417
- indoor air pollutant, 366
- lung clearance mechanisms, toxic effects, 424

NITROSAMINES

- indoor air pollutants, 366

Nonsmokers See PASSIVE SMOKING

NOSE

- irritation following acute exposure to tobacco smoke, 386

NURSES

- involvement in community intervention studies, 514

OCCUPATIONS

(See also **WORKPLACE**)

- coal miners, 230, 234, 240
- grain elevator workers, 31
- industrial workers, 277
- iron foundry workers, 42
- physicians, 14-15, 194, 198, 206, 208, 210-211, 455-488, 511, 514, 527
- shipyard workers, 482-483
- steelworkers, 30, 43
- textile workers, 225, 242

OZONE

- lung clearance mechanisms, toxic effects, 424
- preexposure and cigarette smoke effects in animals, 437

PAPAIN

- emphysema pathogenesis, role, 265-266

PARENTAL SMOKING

(See also **MATERNAL SMOKING**)

- children's encouragement to quit, effect, 519-520
- influence on adolescent smoking rates, 506
- pulmonary function in children, 397-398, 405
- respiratory infections in children, 393, 397, 405
- respiratory symptoms in children, 13, 388-389, 392, 403, 405

PARTICULATES

(See also **TARS, TOBACCO**)

PARTICULATES—Contd.

- aerodynamic diameter, 418-420, 438
- exposure measurement, 383
- indoor air pollutants, 366
- ingestion by pulmonary macrophages, 259
- lung deposition, 420-422, 425, 438
- lung retention, 423-424

PASSIVE SMOKING

- acute airway response, 384, 386
- children, respiratory infections related to parental smoking, 393, 397
- children, subsequent susceptibility to COLD, 7
- COLD risk effect, 13
- deposition of particulates in lungs, 425
- exposure measurement, 316, 383-384
- patients with preexisting pulmonary disease, 403-405
- prevalence of respiratory symptoms, 66
- pulmonary function in children, parental smoking relationship, 397-402
- pulmonary function relationship, 402-403
- sidestream vs. mainstream smoke, 365-366
- symptomatic responses, 386-392

PEPSIN

- emphysema induction in experimental animals, 123

PEPTIC ULCER

- contraindication for nicotine chewing gum, 477

PEROXIDASE

- transfer across tracheal epithelium, 431

PERSONALITY

- cessation of smoking factor, 469, 481-482, 485

PHENOL

- mucociliary transport effects, 295-296

PHENYLMETHYLOXADIOZOLE

- anticiliotoxic effects, 296

PHENYLVINYLOXADIOZOLE

- anticiliotoxic effects, 296

INDEX

Phlegm See MUCUS HYPER-SECRETION

PHYSICIANS

- cessation of smoking and COLD mortality, 210-211
- COLD mortality, 194, 198, 206, 208
- involvement in community intervention studies, 511, 514, 527
- smoking cessation in patients, role, 14-15, 455-488
- smoking prevalence, 14, 456

PIPE SMOKERS

- COLD mortality, 10, 211-212, 214
- cough and phlegm prevalence, 48
- emphysema incidence at autopsy, 240
- former cigarette smokers, 460

PNEUMOCONIOSIS

- pathology, 225, 234

PNEUMONIA

- children of smoking parents, 13, 393, 405

POLONIUM

- deposition at site of bronchogenic carcinoma, 424
- particulate phase component, 417

POLYCYCLIC AROMATIC

HYDROCARBONS

- fibroblast membrane effects, 438

Polymorphonuclear leukocytes See NEUTROPHILS

PREGNANCY

- (See also **MATERNAL SMOKING**)
- antibody production in pregnant smokers, 280
- cessation of smoking, 14, 479-480, 487
- motivation for quitting, 484
- physician intervention and cessation of smoking, 461-465

PREVENTION OF SMOKING

- community intervention studies, 15, 520-524

PROTEASE-ANTIPROTEASE

IMBALANCE

- alpha₁-antitrypsin deficiency, 130
- effect of oxidants, 275
- emphysema pathogenesis, 11, 262, 270-278, 301, 339-340
- smoke exposure effect, 277-278

PULMONARY FUNCTION

- airway lesions relationship, 227, 229
- asthma patients, 13, 403, 405-406

PULMONARY FUNCTION—Contd.

- children of smoking parents, 13, 393, 397-398, 405
- chronic airflow obstruction, 42-44, 68-118, 223-232
- cigarette smoke effects, 6, 9, 191, 427-430, 438
- emphysema, 121-122
- expiratory airflow obstruction as COLD disease process, 21
- inflammation and small airways dysfunction, 11
- inhalation depth relationship, 349
- low yield cigarettes relationship, 337-338, 354
- occupational exposure relationship, 107
- passive smoking effects, 13, 384-386, 402-403, 405
- people deficient in alpha₁-antitrypsin, 262
- small airways dysfunction, 22-44, 136-137, 227

RACIAL/ETHNIC DIFFERENCES

- cessation of smoking during pregnancy, 462
- chronic airflow obstruction, prevalence, 78
- COLD mortality, 11, 191, 214
- COLD risk, 212-213
- serum concentrations of alpha₁-antitrypsin, 263
- smoking prevalence trends, 504

RECIDIVISM

- post-MI patients, environmental factors, 475
- pregnant smokers, before end of pregnancy, 463

REDUCTION OF SMOKING

(See also CESSATION OF SMOKING)

- physician intervention, effectiveness, 458-459
- pregnant women, 463-465
- psychologist's advice, effectiveness, 468-469

RESPIRATORY SYNCYTIAL

VIRUS INFECTION

- children of smoking mothers, 393, 397

SEX DIFFERENCES

- airflow obstruction prevalence, 78, 83

INDEX

SEX DIFFERENCES—Contd.

- cessation of smoking, 468
- cessation rates in post-MI patients, 475
- cholesterol reduction, 512
- chronic bronchitis mortality, 210
- chronic bronchitis prevalence, 46–47
- COLD mortality, 10, 189, 192, 203–207, 213–214
- community intervention effectiveness, 511, 514
- cough and phlegm prevalence, 48, 65–68
- emphysema incidence at autopsy, 240–241
- emphysema severity at autopsy, 241–242
- particulates deposition, 423
- preventive effect of school-based smoking interventions, 522
- pulmonary function after passive smoking, 384–386
- reduction of smoking following physician intervention, 458–459
- small airways dysfunction, 9, 28, 37–40, 137
- smoking patterns and pulmonary function, 32–33, 35, 104
- smoking prevalence, 504

Small airways disease *See* PULMONARY FUNCTION

SMOKING BEHAVIOR

- cigarette yields, effect, 13, 64, 334–335
- inhalation pattern and cessation probability, 469
- inhalation pattern and COLD mortality, 208–209, 214
- inhalation pattern and COLD susceptibility, 7, 348–352, 354
- low yield cigarettes relationship, 12–13, 341–348, 354
- lung deposition of particulates, effect, 420–423, 425
- lung injury relationship, 341

SMOKING INTERVENTION STUDIES

(*See also* ANTISMOKING CAMPAIGNS)

- cessation and prevention effects, 15
- community cessation studies, 504–505, 507–520, 528

SMOKING INTERVENTION STUDIES

- community prevention studies, 520–524, 528
- methodological issues, 524–526, 528
- research needs, 526–528
- theoretical basis, 505–507

SMOKING-MACHINES

- comparability to actual smoking behavior, 12, 64, 333–336, 341, 354, 420–421

SMOKING PATTERNS

- age of initiation and COLD mortality, 209–210
- alveolar macrophage changes and amount smoked, 256
- cessation probability and amount smoked, 459, 469, 481
- COLD morbidity relationship, 9
- COLD mortality and amount smoked, 10, 198, 201, 203, 205–208, 210–211, 213–214
- COLD severity relationship, 336
- cough and phlegm prevalence, 9, 47–48, 137
- determinants of airflow obstruction, 92, 103–104
- emphysema at autopsy and amount smoked, 240–241
- emphysema severity, 10, 137
- emphysematous changes and amount smoked, 126–127
- mucus hypersecretion and amount smoked, 63–65
- pulmonary function and amount smoked, 6–7, 9, 69, 115, 117, 131, 137
- respiratory symptoms prevalence, 73
- small airways dysfunction and amount smoked, 32–35, 39, 43, 136–137

SMOKING PREVALENCE

- physicians, 456, 487
- trends in various demographic groups, 503–504

SOCIOECONOMIC STATUS

- cessation of smoking, relationship, 468–469
- pulmonary function relationship, 108
- reduction in tobacco consumption in higher income groups, 503
- smoking prevalence, 525–526, 528
- trend toward reduced smoking, 15

INDEX

Sputum *See* **MUCUS HYPER-SECRETION**

STRESS

- cessation success relationship, 481-482
- chronic smoking relationship, 527
- management training to maintain nonsmoking, 509

SUPEROXIDE DISMUTASE

- activity depression by tobacco smoke, 434
- reduction of smoke effects on alpha₁-protease inhibitor, 436

SUPEROXIDE RADICALS

- alpha₁-protease inhibitor activity, effect, 436
- generation by alveolar macrophages in smokers, 259, 432
- release from neutrophils in smokers, 433

TARS, TOBACCO

- (*See also* **PARTICULATES**)
- ciliotoxic effect, 295
- cough and phlegm production relationship, 337
- exposure in nonsmokers, 384
- mucus hypersecretion relationship 12, 339
- pulmonary function relationship, 338
- respiratory symptoms effect, 65
- smoking behavior relationship, 13, 347-348, 354

TAXES

- increases as part of community intervention trials, 514

TAXES—Contd.

- revenues contributed by tobacco industry, 503
- smoking deterrent effectiveness, 457, 507, 520, 527

THIOCYANATE

- plasma levels to validate self-reports of cessation, 512
- saliva levels to validate self-reports of cessation, 464
- serum levels to validate self-reports of cessation, 508-509, 511, 513, 518, 521-522

TOBACCO SMOKE

- aerosol characterization, 417-420, 438
- deposition and toxicity, 14
- mainstream vs. sidestream smoke, 365-366
- toxicology, 426-439

TRACHEA

- epithelial permeability in smoke-exposed animals, 430-431

WHEEZING

- children of smoking parents, 388-389, 392-393

WOOD SMOKE

- airflow obstruction, etiologic factor, 83

WORKPLACE

- (*See also* **OCCUPATIONS**)
- air pollution and pulmonary function, 31
- smoking prohibitions and cessation, 457